Direct answer:In the United States, labels and instructions should be reviewed for product classification, intended use, user population and applicable listing. The scope of the check includes the responsible party, purpose, warning operations, packaging and application of UDI; Prescription, non-prescription, IVD or other specific devices cannot be subject to identical lists. The audit documents do not amount to FDA label approval or substitute for the original listing requirements for products.

The product and the basis are determined and the text and drawings are changed. The English translation, information compliance review, layout of scripts and formal monitoring of submission are different tasks and should be clearly defined.

I. What are the specific materials included in the labelling review?

Label is not allowed to look only at the front of the box, unlike the scope of the labeling. The labels, layers of packaging, instructions and accompanying materials and associated declarations shall be combed and checked for consistency with the product’s use, user and listing basis.

Generally based on the general labelling requirements of 21 CFR Part 801; IVD etc. also needs to check Part 809 or other special provisions. Prescription and non-prescription, household and professional uses also affect the use of instructions and other information requirements.

II. How can the basis be established prior to the audit?

The classification of products, product codes, application of 510(k), De Novo, PMA or exemption basis, as well as current intended uses, adaptive conditions and technical information are checked first. Where there is no information to support it, it should be included as a matter for confirmation and should not be supplemented by mere reference to competitors ' labels.

In the case of licensed or approved products, the consistency of the proposed sales version with the corresponding records and applicable controls should be reconciled. See you on the path.Comparison of path before listing。

III. How are responsible parties, names and basic information checked?

  • Whether product names, brands, models are consistent with real products and information.
  • The description of the label enterprise information and relationships, such as manufacturing, packaging or distribution, is accurate.
  • The completeness and clarity of quantity, packaging, conditions of use and other applicable basic information.
  • Whether there is a basis for the applicable content such as lot numbers, serial numbers, dates, sterile or individual use.
  • English and other languages, graphical symbols, presentation and readability meet specific requirements.

Not every device must display the same set of contents, which should be judged according to the applicable rules. Where distributors are listed on the label, their relationship with the manufacturer should also be accurately expressed.

IV. How are the uses, warnings and operational instructions reviewed?

Check the applicable uses, taboos, warnings, attention, installation operations, storage, maintenance or reprocessing in conjunction with the target user, use of environmental and risk information. The description should be consistent with the actual design and validation basis, and it would not be appropriate to delete the key condition into a generic reminder.

Devices that need to be operated by patients or lay users should also be checked for their understanding and implementation of the applicable instructions. The application of prescription limits, specific instrument requirements or instructions for the delivery of documents is subject to a separate judgement, and a two-dimensional code cannot be implied as a substitute for all accompanying requirements.

V. How should the UDI and database interface?

Align labels with DI, PI type, model version and quantity on the packing hierarchy to the GUDID master data and code list after checking applicability. Direct markings are subject to independent applicability conditions and their relationship to labels and records should also be checked.

The label clearance does not automatically include the issuance of a service transaction, a GUID or a Device Listing submission. Details of these mattersUDI/GUDID GuideandGuide to registered listing。

VI. What information is prepared prior to consultation and how is it delivered?

  • Complete labels and instructions, all packages to be sold and language versions.
  • Summary of product uses, model specifications, design techniques and risk information.
  • Classification basis, licence or exemption and existing label-related regulatory records.
  • Liability for manufacturing, packaging, distribution and labelling.
  • UDI, Packaging Level and database information available.
  • Proposed changes to content, supporting basis, data owner and version schedule.

It is recommended that the revised text be reviewed on a rotational basis, depending on the location of the problem, the basis, the proposed changes and the information to be added. Translation, rewriting, design layout, validation studies and formal submission should be clear before commissioning.

VII. CHANGE, PERIODIC ISSUES

Can the new use be changed to a letter of instruction?Changes in use, technology or important warnings may affect pre-market requirements and other records and should be preceded by an evaluation of regulatory and technical impacts.

If the factory is registered, can the labels write the FDA application?Registration or listing is not a product authorization basis; The presentation of the FDA status should be accurate and supported by the corresponding facts.

How long will it be cleared and how will it be charged?Delivery plans and service fees are based on the number of labels, product complexity, completeness, language and review of rotation agreements. This document review is not a uniform FDA review process; Other applications or technical work are listed separately.

VIII. ACCOUNTABILITY AND ACCOUNTABILITY

View medical device labels and instructions for review and preparation of information

Submission of product and business summaries, terms of reference and quotations

Official data checks and updates: 2026-11-06. Author: Mr. Otsun; Audit: Mr. Toto. Specific applicability and handling arrangements should be checked against the current FDA rules for the combination of equipment, entrepreneurial activities and FDA.

Continue reading and preparation

Further consolidation of project information is availableCheckup for labels and instructions; The scope, processing cycles and costs are shown on the corresponding service page.